Skip to content

Veru Stock Surges 66% After Positive Breast Cancer Trial Results

Biopharmaceutical company Veru Inc (NASDAQ: VERU) shares are up over 65% on Monday after the company said its VERU-111 treatment has anti-cancer activity in Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors.

VERU-111 is an oral cytoskeleton disruptor that is currently being evaluated in both Phase 1b and Phase 2 clinical trials in men with prostate cancer. Veru said that in the prostate cancer clinical trials, the treatment has significant anti-tumour efficacy.

The company said that concerning breast cancer, “triple-negative breast cancer cells implanted into mice, orally administered VERU-111 almost completely inhibited tumour growth, whereas the placebo-treated tumours increased more than 10-fold.”

The company now plans to meet with the FDA in the first half of 2021 and advance VERU-111 into Phase 2b clinical trials in women with metastatic triple-negative breast cancer in 2021.  

After opening the session at $10.82 per share, Veru Inc’s stock is now at $10.57, up 66.48% on the day. 

PEOPLE WHO READ THIS ALSO VIEWED:

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.